DTC And The Art Of Selling An Establishment Pricing Plan To A Populist President
The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.
You may also be interested in...
Treating mandatory wholesale acquisition cost disclosure in TV ads as a major drug pricing reform is close to ludicrous. But the broad approval of the action is an important sign of the continued public image cost of the ads to the drug companies.
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.
The reform 'blueprint' might actually live up to its hype.